• Гормональная контрацепция у несовершеннолетних и женщин молодого возраста, взаимосвязь с исходами беременности и родов

Гормональная контрацепция у несовершеннолетних и женщин молодого возраста, взаимосвязь с исходами беременности и родов

HEALTH OF WOMAN. 2017.4(120):86–92; doi 10.15574/HW.2017.120.86

Веропотвелян П. Н., Радченко В. В., Пивнева Н. В., Осадчук Е. Г.
«Межобластной центр медицинской генетики и пренатальной диагностики», г. Кривой Рог
ФПО «Днепропетровская медицинская академия», г. Кривой Рог
Центр планирования семьи и репродукции человека», г. Кривой Рог

Беременность и роды у несовершеннолетних нуждаются в пристальном внимании врачей разных специальностей – психологов, терапевтов, эндокринологов и акушеров-гинекологов ввиду высокой частоты осложнений. При этом важную роль играют вопросы планирования семьи и медико-социальной помощи подросткам и женщинам молодого возраста с гарантированными информационными услугами и эффективным консультированием в аспекте улучшения демографической ситуации в стране и состояния здоровья населения. Комбинированные оральные контрацептивы являются рекомендованными у несовершеннолетних одновременно с использованием барьерной контрацепции.

Ключевые слова: несовершеннолетние, контрацепция, осложнения беременности и родов.

Литература:
1. Lethaby A., Irvine G.A., Cameron I.T. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2008.

2. Fleming K.L., Sokoloff A., Raine T.R. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception. 2010; 82(2): 178–82. https://doi.org/10.1016/j.contraception.2010.02.020; PMid:20654760 PMCid:PMC3153421

3. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin. Drug Investig. 2010; 30(11): 749–63. https://doi.org/10.2165/11538900-000000000-00000; PMid:20818837

4. Winner B., Peipert J.F., Zhao Q., Buckel C., Madden T., Allsworth J.E., Secura G.M. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 2012; 366(21): 1998–2007. https://doi.org/10.1056/NEJMoa1110855; PMid:22621627

5. United Nations (UN). Proclamation of Teheran, Final Act of International Conference on Human Rights. Teheran, May13, 1968. U.N. Doc. A/CONF. 32/41 at 3 (1968). New York: United Nations; 1968.

6. Egarter C., Frey Tirri B., Bitzer J., Kaminskyy V., Oddens B.J., Prilepskaya V. et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health. 2013; 13: 9. Available at: http://www.ncbi.nlm.nih.gov/. https://doi.org/10.1186/1472-6874-13-9; PMid:23448283 PMCid:PMC3605181

7. Ersek J.L., Brunner Huber L.R., Thompson M.E., Warren-Findlow J. Satisfaction and discontinuation of contraception by contraceptive method among university women. Matern. Child Health J. 2011; 15(4): 497-506. https://doi.org/10.1007/s10995-010-0610-y; PMid:20428934

8. Moreau C., Cleland K., Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76(4): 267–72. https://doi.org/10.1016/j.contraception.2007.06.008; PMid:17900435

9. Prilepskaya V.N. Hormonal contraception. Clinical lectures. M.: GEOTAR-Media 2014; 12–7.

10. Mihailin ES, Ivanova LA, Savitsky AG, Berlev IV Legal consequences of pregnancy and labor in minors//Obstetrics and gynecology. 2015. 17: 63–67.

11. Dikke G.B.Gormonalnaya contraceptives in young women – preferences, expectations, commitment //Obstetrics and gynecology. 2015. 11: 28–35.

12. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. The use of contraception outside the terms of the product licence//J Fam Plan Reprod Health Care 2005: 31 (3): 225–242. https://doi.org/10.1783/1471189054483780; PMid:16105289

13. Kuznetsova I.V.. Metabolic effects of combined hormonal contraception and the risk of thrombotic oslojnenii. Obstetrics and Gynecology. 2016; 6:108-114.

14. Gallo M.F., Nanda K., Grimes D.A., Lopez L.M., Schulz K.F. 20 g versus >20 g estrogen combined oral contraceptives for contraception. (Review). Cochrane Database Syst. Rev. 2013; (8): CD003989. Available at: http: //onlinelibrary. wiley.com/. PMid:23904209

15. Endrikat J., Parke S., Trummer D., Schmidt W., Duijkers I., Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008; 78(3): 218–25. https://doi.org/10.1016/j.contraception.2008.05.004; PMid:18692612

16. Ahrendt H.J., Makalova D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436–44. https://doi.org/10.1016/j.contraception.2009.03.018; PMid:19835717

17. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab. 1995; 80(6): 1816–21. https://doi.org/10.1210/jcem.80.6.7775629; https://doi.org/10.1210/jc.80.6.1816

18. Losert W., Casals-Stenzel J., Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985; 35(2): 459–71. PMid:4039568

19. Nakajima S.T., Archer D.F., Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin 24 Fe). Contraception. 2007; 75(1): 16-22. https://doi.org/10.1016/j.contraception.2006.08.004; PMid:17161118

20. Karahalis L.Y, Zhigalenko A.R., Steblo E.I. Contraceptive and non-contraceptive effects of drospirenone. Reproductive health of children and adolescents. 2015; 2: 73-7.

21. Willis S.A., Kuehl T.J., Spikerman A.M., Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006; 74(2): 100-3. https://doi.org/10.1016/j.contraception.2006.02.006; PMid:16860046

22. Caiyan W., Wen D., Qinping L., Huan S., Ziyan H., Liangdan T. et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(5): 355–9. PMid:25030732

23. Fu Y., Mi W., Li L., Zhang H., Wang J., Cheng W. et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(7): 506–9. PMid:25327732

24. Mansour D., Verhoeven C., Sommer W., Weisberg E., Taneepanichskul S., Melis G.B. et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17?-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept. Reprod. Health Care. 2011; 16(6): 430–43. https://doi.org/10.3109/13625187.2011.614029

25. Gevorgyan M.A., Manukhin I.B., Tikhomirov A.L., Kuznetsova E.M. Experience in the use of drospirenone-containing hormonal contraceptives. Russian Medical Journal. in 2011; 19 (1): 24-33.

26. Prilepskaya V.N., Novikova E.P. Drospirenone-containing contraceptives – the possibilities are expanding. Farmateka. 2012; 12: 49–52.

27. Tikhomirov AL Combination composition and demand for hormonal contraception. Russian Medical Journal. 2014; 22 (1): 38–40.

28. Gallo M.F., Lopez L.M., Grimes D.A., Carayon F., Schulz K.F., Helmerhorst F.M. Combination contraceptives: effects on weight. (Review). Cochrane Database Syst. Rev. 2014; (1): CD003987. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD003987.pub5

29. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000; 62(1): 29–38. https://doi.org/10.1016/S0010-7824(00)00133-5

30. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care. 2000; 5(2): 124–34. https://doi.org/10.1080/13625180008500387

31. Lawrie T.A., Helmerhorst F.M., Maitra N.K., Kulier R., Bloemenkamp K., Gulmezoglu A.M. Types of progestogens in combined oral contraception: effectiveness and side-effects. (Review). Cochrane Database Syst. Rev. 2011; (5): CD004861. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD004861.pub2

32. Nappi R.E., Albani F., Tonani S., Santamaria V., Pisani C., Terreno E. et al. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct. Neurol. 2009; 24(2): 71–5. PMid:19775533

33. Apter D., Borsos A., Baumgartner W., Melis G.B., Vexiau-Robert D., Colligs-Hakert A. et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Health Care. 2003; 8(1): 37–51. https://doi.org/10.1080/ejc.8.1.37.51; https://doi.org/10.1080/713604397; PMid:12725674

34. Gruber D.M., Huber J.C., Melis G.B., Stagg C., Parke S., Marr J. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 µg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 µg and desogestrel 150 mug. Treat. Endocrinol. 2006; 5(2): 115–21. https://doi.org/10.2165/00024677-200605020-00005; PMid:16542051

35. Marr J., Heinemann K., Kunz M., Rapkin A. Ethinylestradiol 20 µg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int. J. Gynaecol. Obstet. 2011; 113(2): 103-7. https://doi.org/10.1016/j.ijgo.2010.10.029; PMid:21338987

36. Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 2008; 53(9): 729–41. PMid:18980045

37. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. (Review). Cochrane Database Syst. Rev. 2012; (2): CD006586. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD006586.pub4

38. Wong C.L., Farquhar C., Roberts H., Proctor M. Oral contraceptive pill for primary dysmenorrhoea. (Review). Cochrane Database Syst. Rev. 2009; (4): CD002120. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD002120.pub3; https://doi.org/10.1002/14651858.CD002120.pub2

39. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. (Review). Cochrane Database Syst. Rev. 2012; (7): CD004425. Available at: http://onlinelibrary.wiley.com/. https://doi.org/10.1002/14651858.CD004425.pub5

40. van Vloten W.A., van Haselen C.W., van Zuuren E.J., Gerlinger C., Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002; 69(4, Suppl.): 2–15. PMid:12096825

41. Maloney J.M., Dietze P. Jr., Watson D., Niknian M., Lee-Rugh S., Sampson-Landers C., Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet. Gynecol. 2008; 112(4): 773–81. https://doi.org/10.1097/AOG.0b013e318187e1c5

42. Koltun W., Lucky A.W., Thiboutot D., Niknian M., Sampson-Landers C., Korner P., Marr J. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008; 77(4): 249–56. https://doi.org/10.1016/j.contraception.2007.11.003; PMid:18342647

43. Artymuk N.V., Bukreeva E.L. Comparative evaluation of the effect of a combination of 3 mg of drospirenone and 20 or 30 mcg ethinyl estradiol to the skin condition and anthropometric indices. Farmateka. 2015; 3: 31–3.

44. Hodzhibayeva T. Y. Features of preconception period at primapara women /T.Y.Hodzhibayeva, N.N.Zaripov, M.M. Rakhimov //Materials IX of the Russian forum «Mother and child». – M, 2007. – P. 289.

45. Krotin PN, Yur’ev VK, Kulikov AM. The reproductive potential of modern teenage girls and ways to preserve it. Gedeon Rihter v SNG. 2001; 3; 5–8.

46. Mikhalin E.S., Ivanova L.A., Savitsky A.G., Berlev I.V. Comparative characteristics of pregnancy and delivery complications in minor and middle reproductive-aged women // Russian Vestnik obstetrician-gynecologist. – 2016. – № 3 (том 15) – Р. 60–63. https://doi.org/10.17116/rosakush201616360-63

47. Sinchihin SP, Kokolina VF, Mamiev OB. Pregnancy and childbirth among minors. Pediatriya. 2004;3:93–96.

48. Ruedinger E., CoxJ.E. Adolescent childbearing: consequences and interventions. Curr Opin Pediatr 2012; 24:4: 446–452. https://doi.org/10.1097/MOP.0b013e3283557b89

49. Rowlands S. Social predictors of repeat adolescent pregnancy and focussed strategies. Best Pract Res Clin Obstet Gynaecol 2010; 24: 5: 605–616. https://doi.org/10.1016/j.bpobgyn.2010.02.016; PMid:20363195

50. Ferraro A.A., Cardoso V.C., Barbosa A.P. Childbearing in adolescence: intergenerational deja-vu? Evidence from a Brazilian birth cohort. BMC Pregnancy Childbirth 2013; 15: 13–19. https://doi.org/10.1186/1471-2393-13-149

51. James A.H. Obstetric management of adolescents with bleeding disorders. J Pediatr Adolesc Gynecol 2010; 23: 6: 31–37. https://doi.org/10.1016/j.jpag.2010.08.004; PMid:20934895

52. Malamitsi-Puchner A., Boutsikou T. Adolescent pregnancy and perinatal outcome. Pediatr Endocrinol Rev 2006; 3: 170–171. PMid:16641854

53. Joshi М., Gumashta R. Weekly iron folate supplementation in adolescent girls-an effective nutritional measure for the management of iron deficiency anaemia. Glob J Health Sci 2013; 5: 3: 188–194. https://doi.org/10.5539/gjhs.v5n3p188

54. McCracken K.A., Loveless M. Teen pregnancy: an update. Curr Opin Obstet Gynecol 2014; 26: 5: 355–359. https://doi.org/10.1097/GCO.0000000000000102; PMid:25136760

55. Pinzon J.L., Jones V.F. Care of adolescent parents and their children. Pediatrics 2012; 130: 6: 1743–1756. https://doi.org/10.1542/peds.2012-2879; PMid:23184113

56. Ganchimeg Т., Ota E., Morisaki N. Pregnancy and childbirth outcomes among adolescent mothers: a World Health Organization multicountry study. BJOG 2014; 121: 40–48. https://doi.org/10.1111/1471-0528.12630; PMid:24641534

57. Paranjothy S., Broughton H., Adappa R. Teenage pregnancy: who suffers? Arch Dis Child 2009; 94: 3: 239–245. https://doi.org/10.1136/adc.2007.115915; PMid:19019886

58. Mikhailin E.S., Ivanova L.A. Specific features of teenage pregnancy and delivery in relation to age /// Russian Vestnik obstetrician-gynecologist. – 2015. – № 2 (том 15) – Р. 68–74.